PA
SYRE icon

Perceptive Advisors’s Spyre Therapeutics SYRE Stock Holding History

Perceptive Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$383M Buy
4,319,496
+536,271
+14% +$39.1M 5.76% 2
2026
Q1 		$191M Buy
3,783,225
+714,000
+23% +$26.9M 3.73% 7
2025
Q4 		$101M Buy
3,069,225
+1,839,780
+150% +$48.1M 1.79% 15
2025
Q3 		$20.6M Sell
1,229,445
-300,000
-20% -$4.89M 0.6% 45
2025
Q2 		$22.9M Sell
1,529,445
-783,827
-34% -$11.6M 0.85% 31
2025
Q1 		$37.3M Sell
2,313,272
-261,451
-10% -$5.44M 1.32% 22
2024
Q4 		$59.9M Sell
2,574,723
-297,824
-10% -$8.73M 1.65% 17
2024
Q3 		$84.5M Sell
2,872,547
-158,471
-5% -$4.41M 1.79% 15
2024
Q2 		$71.3M Buy
3,031,018
+474,339
+19% +$16M 1.72% 15
2024
Q1 		$97M Sell
2,556,679
-50,000
-2% -$1.45M 1.7% 16
2023
Q4 		$56.1M Buy
2,606,679
+2,525,563
+3,114% +$34.8M 1.25% 23
2023
Q3 		$994K Buy
+81,116
New +$1.07M 0.03% 87
2018
Q3 		– Sell
-1,028
Closed -$272K – 130
2018
Q2 		$272K Buy
+1,028
New +$253K 0.01% 119
2017
Q2 		– Sell
-233
Closed -$43K – 154
2017
Q1 		$43K Sell
233
-3,910
-94% -$552K ﹤0.01% 139
2016
Q4 		$451K Hold
4,143
– – 0.03% 125
2016
Q3 		$664K Sell
4,143
-93
-2% -$12.9K 0.04% 104
2016
Q2 		$515K Buy
+4,236
New +$812K 0.04% 117

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Perceptive Advisors's SYRE Position: Q2 2026 in Review

Perceptive Advisors increased its Spyre Therapeutics (SYRE) stake by 14% in Q2 2026, buying an estimated $39.1M and bringing the position to 4,319,496 shares worth $383M. The position accounts for 5.76% of the portfolio, ranked #2.

Perceptive Advisors first reported a position in SYRE in Q2 2016 and has held it in 17 quarters since. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Perceptive Advisors held 4,319,496 shares of Spyre Therapeutics worth $383M as of Q2 2026.
  • Perceptive Advisors bought 536,271 Spyre Therapeutics shares in Q2 2026, an estimated $39.1M.
  • Spyre Therapeutics made up 5.76% of Perceptive Advisors's portfolio in Q2 2026, its #2 holding.
  • Perceptive Advisors first reported a position in Spyre Therapeutics in Q2 2016 and has held it in 17 quarters since.
  • 266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.